Mirae Asset Global Investments Co. Ltd. Increases Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 31.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 99,314 shares of the biopharmaceutical company’s stock after purchasing an additional 23,715 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.08% of Novavax worth $477,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its position in Novavax by 467.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,743 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 11,319 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Novavax in the 3rd quarter worth $72,000. Hodges Capital Management Inc. bought a new position in Novavax in the 3rd quarter worth $72,000. Nomura Holdings Inc. purchased a new position in Novavax during the third quarter valued at $74,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Novavax during the third quarter valued at about $76,000. Institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their price objective on Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

Novavax Price Performance

Shares of NASDAQ NVAX opened at $4.09 on Friday. The stock has a market cap of $572.40 million, a PE ratio of -0.74 and a beta of 1.59. Novavax, Inc. has a 1 year low of $3.53 and a 1 year high of $11.36. The firm has a fifty day moving average price of $4.70 and a 200-day moving average price of $5.12.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.95). The business had revenue of $291.34 million during the quarter, compared to analyst estimates of $310.96 million. During the same period in the previous year, the firm earned ($2.28) EPS. The business’s quarterly revenue was down 18.5% compared to the same quarter last year. On average, research analysts expect that Novavax, Inc. will post -0.83 EPS for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.